Potential therapeutic agents for ischemic white matter damage.

Area of Science:

• Neuroscience
• Neurology
• Pathology

Background:

• Ischemic white matter damage (WMD) is a significant cause of neurological disorders in older adults and preterm infants.
• WMD leads to progressive cognitive decline and dementia, especially in patients with ischemic cerebrovascular diseases.
• Despite advances in understanding pathogenesis, effective treatments for ischemic WMD remain unavailable.

Purpose of the Study:

• To review animal models, pathological mechanisms, and potential therapeutic agents for ischemic white matter damage.
• To summarize the current research on antioxidants, free radical scavengers, anti-inflammatory, anti-apoptotic agents, and neurotrophic factors for WMD.
• To identify promising therapeutic strategies for clinical translation.

Main Methods:

• Literature review of studies on ischemic white matter damage.
• Analysis of pathological mechanisms and therapeutic interventions.
• Synthesis of findings on various classes of potential therapeutic agents.

Main Results:

• Various agents, including antioxidants, free radical scavengers, anti-inflammatory, and anti-apoptotic drugs, have been studied for WMD.
• Neurotrophic factors show potential in mitigating WMD.
• Agents that protect or promote oligodendrocyte health are promising.

Conclusions:

• There is an urgent need for effective treatments to slow or modify the course of ischemic WMD.
• Therapeutic agents targeting oligodendrocyte damage or proliferation/differentiation hold potential value.
• Drugs with multifaceted protective activities and a wide therapeutic window are optimal for clinical application.